Health Advisory: Paxlovid Granted EUA and Testing Before Gathering

Actions Requested

For questions, please contact our Communicable Disease staff at 360-728-2235.


As Omicron cases surge in our region—and communities gather for the holidays—we welcome news of additional tools to combat COVID-19 and reduce the burden on our healthcare systems. We are working with DOH and local healthcare partners to establish equitable access and distribution as these therapeutics become available.

Paxlovid and Ritonavir

Paxlovid and ritonavir prescribing information is contained in their EUAs:

  • Before prescribing, clinicians should carefully review drug interaction.
  • Paxlovid is provided as 2 pink 150 mg tablets co-packaged with 1 white 100 mg tablet of ritonavir. People already taking ritonavir for another condition should be counseled to not take the white tablet with their dose. These medications should be taken as a single dose at the same time every day.
  • This combination therapy has not been studied during pregnancy or lactation but the EUA does allow for use in this population with proper informed consent.
  • Paxlovid should not be used by people with severe liver and/or renal disease. People with moderate reductions in renal function may require dose modifications.

Paxlovid and ritonavir supplies will be significantly limited initially. We await guidance from DOH on how many doses will be allocated to Washington and where they will be sent.

Kitsap COVID Case and Vaccine Trends

Average cases over the past 7 days have been increasing. Kitsap is now experiencing “high” transmission (100+ cases per 100,000 population) with an average of 112.4 cases per 100,000 population.

New COVID-19 hospitalizations were at 19 for the week ending 12/18/2021.

To date, we have had 262 Kitsap resident COVID-associated deaths.

The rate of infection among unvaccinated individuals was 2.4 times higher than among fully vaccinated. In the past 30 days, unvaccinated people age 12-59 were 5.6 times more likely and adults age 60 and older were 2.6 times more likely to be hospitalized for COVID-19 than those fully vaccinated.

As of December 21, 2021, 76.6% of Kitsap residents age 5 and older had initiated vaccination, 69.9% were fully vaccinated. Vaccination initiation rates are lowest in adults age 19-34 (66%), residents of Bremerton (66%) and Central Kitsap (68%), Black/African American (49%), and males (67%). So far, 26% of Kitsap children age 5-11 have initiated vaccination.

The chart below provides trend over time of vaccine doses administered to Kitsap County residents. On the right, light blue indicates the number of additional/booster doses administered.

Additional Information

COVID-19 Vaccine

COVID-19 Testing

COVID-19 Therapeutics

HHS allocates monoclonal antibody and oral antiviral supplies to each state. DOH distributes doses to enrolled providers. Providers must enroll in HPoP to manage COVID-19 therapeutics. Email to register for HPoP training, held Tuesdays at 9 a.m.

Find more resources in the COVID-19 monoclonal antibody therapeutics communication toolkit.

COVID-19 Prevention Patient Education

Share the following materials with patients.

Immediately report COVID-19

Contact Kitsap Public Health by calling (360) 728-2235 or faxing our confidential fax (360) 813-1168.

Additional resources